REG - Halma PLC - Trading Update

HalmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260312:nRSL3015Wa&default-theme=true

RNS Number : 3015W  Halma PLC  12 March 2026

Halma plc

Trading update

12 March 2026

 

Halma, the global group of life-saving technology companies focused on growing
a safer, cleaner, healthier future for everyone, every day, today releases its
scheduled trading update ahead of its financial year end on 31 March 2026.

 

Further strong progress in the second half, consistent with existing guidance

We have made further strong progress in the second half of this financial year
to date, consistent with the upgraded guidance given in our Half Year results
published in November 2025. This progress further extends our track record of
delivering strong, compounding growth and returns, and puts us on course to
deliver our 23(rd) consecutive year of record Adjusted profit(1).

 

While our companies continue to experience varied conditions in their end
markets and operate in an increasingly uncertain economic and geopolitical
environment, we have delivered broad-based growth across the Group as we
continue to benefit from the strengths inherent in our Sustainable Growth
Model. These include our participation in diverse end markets where growth is
supported by long-term growth drivers, the autonomy and agility our Model
provides our companies to respond rapidly to changing market conditions, and
the alignment of our exceptional talent across the Group behind our purpose of
growing a safer, cleaner, healthier future for everyone, every day.

 

Based on our progress in the year to date and our current expectations for the
remainder of the year, we continue to expect that we will deliver, in the year
as a whole, mid-teens percentage organic constant currency(2) revenue growth,
including a continued benefit from premium growth in photonics within the
Environmental & Analysis Sector, and an Adjusted EBIT margin(3) (excluding
the one-off profit in the first half) of around 22%(4). We also expect our
full year cash conversion to be in line with our KPI of 90%, supporting our
ongoing strategic investment in future organic growth and in acquisitions, and
ensuring that we maintain a strong financial position.

 

This guidance is supported by order intake which remains ahead of both revenue
in the year to date and the comparable period last year.

 

The appreciation of Sterling is expected to have a negative currency
translation effect on the Group's results(5).

 

Record investment in acquisitions; healthy acquisition pipeline

We have completed five acquisitions in the year to date, three since the half
year ended 30 September 2025, across the Group's three sectors, with a record
£451m invested (on a maximum total consideration basis(6)). We continue to
have a healthy acquisition pipeline across all three sectors.

 

Full Year Results

The Group's results for the year ending 31 March 2026 will be released on 11
June 2026.

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive
    +44 (0)1494 721 111

Carole Cran, Chief Financial Officer
         +44 (0)1494 721 111

Melanie Horton, Co-Head of Investor Relations
+44 (0) 7554 013 396

Charles King, Co-Head of Investor
Relations                        +44 (0) 7776 685 948

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare
        +44 (0)7817 458 804 / halma@mhpgroup.com

Notes:

1. Adjusted profit is Adjusted profit before tax, amortisation and impairment
of acquired intangible assets, acquisition items, and profit or loss on
disposal of businesses.

2. Organic constant currency measures exclude the effect of movements in
foreign exchange rates on the translation of revenue and profit into Sterling,
as well as acquisitions in the year following completion and disposals.

3. Adjusted EBIT is earnings before interest and tax, and before amortisation
and impairment of acquired intangible assets, acquisition items, and profit or
loss on disposal of businesses. Adjusted EBIT margin is defined as Adjusted
EBIT expressed as a percentage of revenue.

4. Our Adjusted(1) EBIT margin guidance excludes the one-off profit from the
Nuvonic transaction which was completed in the first half of this year (see
note 7 below).

5. Sterling has strengthened in the year relative to many currencies,
including the US Dollar and Euro and the currency translation impact on the
Group's results for the financial year ended 31 March 2026 is expected to be
negative. Based on exchange rates of Sterling/US Dollar 1:1.34 and
Sterling/Euro 1:1.16, we would expect approximately a £63m negative revenue
effect and approximately a £14m negative profit effect in the 2026 financial
year, compared to the 2025 financial year.

6. Of the five acquisitions made in the year to date, Nu Perspectives Limited
and MC Steering B.V. (Brownline) were reported in the Group's half year
results announcement. Since that time, we have made three further acquisitions
(considerations given are all on a cash- and debt-free basis):

·    E2S Group Ltd, a manufacturer of high-performance safety
notification, initiation and detection devices primarily used in highly
hazardous environments in heavy industries and complex manufacturing, acquired
in December 2025 for £230m;

·    Safetec Srl, a provider of customised fire and gas safety solutions
for large-scale, complex and high-risk industrial projects, acquired in
January 2026 for €72.5m (approximately £63m); and

·    Altomed, a UK-based manufacturer and distributor of specialised
ophthalmic instruments and consumables, acquired in February 2026 for £29m,
as a bolt-on for MST.

Maximum total consideration is on a cash- and debt-free basis.

7. On 15 May 2025, Nuvonic, an Environmental & Analysis Sector company,
granted FluidSmile Fluid Tech Ltd (FluidSmile), a longstanding partner of
Nuvonic in China, an exclusive trademark licence and related manufacturing and
distribution rights to sell certain Nuvonic products in China and other agreed
southeastern Asian markets, for RMB95m (£9.3m). Nuvonic also acquired a 35%
associate investment in FluidSmile for RMB95m on the same date. As a result of
these transactions, one-off revenue of £9.3m and profit of £8.6m were
recognised in the current financial year.

8. This Trading update is based upon unaudited management accounts
information. Forward-looking statements have been made by the Directors in
good faith using information available up until the date that they approved
this statement. Forward-looking statements should be regarded with caution
because of the inherent uncertainties in economic trends and business risks.

9. A copy of this announcement, together with other information about Halma,
may be viewed on our website www.halma.com (http://www.halma.com/) .

About Halma

Halma is a global group of life-saving technology companies, focused on
growing a safer, cleaner, healthier future for everyone, every day. Its
purpose defines the three broad market areas where it operates:

 ·    Safety           Protecting the safety of people and assets as populations grow and the demand
                       on infrastructure increases.
 ·    Environment      Addressing the impacts of climate change, pollution and waste, protecting
                       life-critical resources and supporting scientific research.
 ·    Healthcare       Meeting the increasing demand for better healthcare as chronic illness rises,

                     driven by growing and ageing populations and lifestyle changes.

Halma employs over 9,000 people in more than 20 countries, with major
operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is
listed on the London Stock Exchange (LON: HLMA) and is a constituent of the
FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past
seven years.

For more information www.halma.com (http://www.halma.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSFUFWFEMSELD



            Copyright 2019 Regulatory News Service, all rights reserved